Treatment resistant Ophthalmoplegia in Myasthenia Gravis

29
Treatment–resistant Ophthalmoplegia in Myasthenia Gravis Jeannine Heckmann Neurology Division University of Cape Town South Africa

Transcript of Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Page 1: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Treatment–resistant Ophthalmoplegia in Myasthenia Gravis

Jeannine HeckmannNeurology DivisionUniversity of Cape TownSouth Africa

Page 2: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Mathilda Karel Spak (1901 – 2005)

Founder of MGFC

Mother had MG symptoms x 20 yrs

Page 3: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Phenotype of OP-MG

Histology

"Genotype"

Dynamic studies

Hypothesis of OP-MG pathogenesis

Treatment-resistant ophthalmoplegia in MG (OP-MG)

Page 4: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Ave annual incidence rate by age at symptom onset 2011-2012 overall ~9 /million/year

men

women

Page 5: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Subgroup of AChR ab+ MG patients

• Treatment resistant ophthalmoplegia• Juvenile onset MG• African genetic ancestry

Page 6: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Postulate: Gene variant(s) have no consequence without MG –

however, MG triggers dysregulation in vulnerable EOMs

African Genetic ancestry in South Africa – racial categories in census

Indigenous black SA

Cape mixed African

Page 7: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Black Africans: colour-coded ancestral gene clusters

West African East African SA

Page 8: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

SA hunter gatherer genomes most diverse-oldest known lineage of modern humans

genome diversity - KhoiSan octogenarians

>13,000 novel amino acid variants

Page 9: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Cape mixed-African: 400 yrs – mainly Khoisan

Page 10: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Delayed onset: EOMs initially responded to therapy and then a critical event triggered OP-MG

Immediate onset: EOMs treatment-resistant from diagnosis while remaining muscles respond

AAO-3 MGFA 2A

MGFA 3A MGFA 5 MGFA 5

MGFA 3BMGFA 4B

AAO-12AAO-2 AAO-16

AAO-17 AAO-28

Page 11: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Every clinic visit: Ophthalmoplegia + MG composite score

Important to document the ophthalmoplegia objectively

Page 12: Treatment resistant Ophthalmoplegia in Myasthenia Gravis
Page 13: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

How frequently do we see OP-MG in the clinic?

• Defined as treatment-resistant ophthalmoplegia > 2 yrs• Self categorized by race

African genetic ancestry are younger

Page 14: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

2007-2017

13 OMG; 74 GMG• Observational• BL weak EOMs• 1st 12 months Rx

Page 15: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Earlier and “aggressive” immune therapies associated with resolution of ophthalmoparesis

<12 mo symptoms + immune therapy/pred. 2x > chance of resolutionMedian resolution early rx group – 4 mo.

Page 16: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

MGFA gr3b : Bilat. ophthalmoparesis x 3 yrs

Control: Stabbed & blind/sensory squint x 3yr

Paralysed medial rectus MG vs control

Z line streamingSubsarcolemmal mitoch.Abnormal mitoch.

OP-MG

OP-MG Control

Page 17: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Neurogenic changesAtrophy of type IIMitochondrial stress

Poor muscle force & contractility

Page 18: Treatment resistant Ophthalmoplegia in Myasthenia Gravis
Page 19: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

PCA plot –2 subpopulations segregate but not OP-MG vs control MG

Page 20: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

P< 1x10-5

P< 1x10-3

Manhatten plot of GW single gene variant association OP-MG vs control MG

Subthreshold analysis: Top 2 ranked regulatory variants in gene promoters - expressed in muscle3x more frequent in Africans > Europeans

Page 21: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

• Unbiased

• Gene-based association analysis of collective putative functional variant burden in genes in OP-MG vs cntrl MG p< 0.015

• Ranked according to GTEx expression level in skeletal muscle

+ Muscle atrophy

+ integrity Myosin HC

Transcripts per million in skeletal muscle

- Satellite cell act.

Page 22: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

MyoDadenovirus

48 hrs

Primary dermal fibroblasts

AdMyoD-myocytes

Figure adapted from C.F. Bentzinger et al. Cold Spring Harb Perspect Biol 2012

Gene expression? Patient-derived myoblast cultures

Page 23: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

homologous 5% MG sera x 24 hrs

OP-MG (10) vs control MG (6)

Gene pair expression levels correlate in nodes (r>0.9; FDR <0.01)

Gene expression array

Page 24: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Surrogate OP-MG muscle model: dysregulated ‘myocyte’ gene expression

suggests functional relationship

• 50% OP-MG genes correlated with 40% MG/EAMG genes • IGF1/AKT pathway –atrophy [EOMs]

• pathway not previously considered relevant in MG correlate with MG/EAMG pathways• Myogenesis & satellite cell activation

• Gangliosphingolipid & glycoprotein synthesis• Integrity of muscle endplate

Page 25: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Mitochondrial stress

EAMG muscles

Histopathology in MG

MGS induced mito. metabgenes in muscle model

vs Non-paralytic strabismus

Page 26: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

* p<0.01 **p<0.001

Metabolic assay: Oc-fibro cultures: 2 OP-MG vs 5 controls

Similar basal OCR and response to “stressor mix”

MG sera induced > energetic phenotype in OP-MG (3x)

Page 27: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Glucose & Glycolysis

*

*

Pathogenesis

Page 28: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

Genetic studiesOP-MG vs cntrl MG*

Dynamic studiesMG sera

Gene expression

MG muscleModel*

Ocular Fibro **

Orbic. Oc**

Gene CD55, TGFB1 -/✓ ?

WGS Muscle atrophy ✓ ?

Mitochondrial metab ✓ ✓ ?

Muscle regeneration ✓ ?

2 ‘muscle’ genes? ?

** vs strabismus cntrl

Histology suggests poor contractility critical in EOMs

SUMMARY

Page 29: Treatment resistant Ophthalmoplegia in Myasthenia Gravis

• Melissa Nel

• Tarin Europa

• Mariba Lebeko

• Robyn Rautenbach

• Lihle Moyakhe

• Sharon Prince

• Nicola Mulder

• Mpopi Lenake (ophthalmologist)

• Tony Murray (ophthalmologist)